{"id":"NCT00672958","sponsor":"Takeda","briefTitle":"Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder","officialTitle":"A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study Comparing the Efficacy and Safety of Lu AA21004 Versus Placebo in Acute Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2008-11","completion":"2008-11","firstPosted":"2008-05-06","resultsPosted":"2013-12-13","lastUpdate":"2013-12-13"},"enrollment":600,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Vortioxetine","otherNames":["Lu AA21004","BrintellixÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Vortioxetine","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the efficacy and safety of once daily vortioxetine (Lu AA21004) in adults with major depressive disorder.","primaryOutcome":{"measure":"Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 6","timeFrame":"Baseline and Week 6","effectByArm":[{"arm":"Placebo","deltaMin":-13.87,"sd":0.662},{"arm":"Vortioxetine","deltaMin":-14.61,"sd":0.65}],"pValues":[{"comp":"OG000 vs OG001","p":"0.407"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":18},"locations":{"siteCount":33,"countries":["United States","Canada","Mexico"]},"refs":{"pmids":["22963932"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":298},"commonTop":["Headache","Nausea","Diarrhoea","Dry mouth","Dizziness"]}}